ARCTArcturus Therapeutics Holdings Inc.

$210M

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-60.8% YoY

Gross Profit

-$9M-304.1% margin

Operating Income

-$11M-364.5% margin

Net Income

-$11M-370.2% margin

EPS (Diluted)

$-0.76

QoQ Revenue Growth

-10.5%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$797,000

Balance Sheet

Total Assets

$82M

Total Liabilities

$56M

Stockholders' Equity

$26M

Cash & Equivalents

$71M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$8M	-60.8%
Gross Profit	-$9M	$3M	-430.6%
Operating Income	-$11M	-$711,000	-1421.4%
Net Income	-$11M	-$1M	-986.9%

ARCT Q4 2019 Earnings — Arcturus Therapeutics Holdings Inc. Revenue & Financial Results | Market Cap Arena